KURA
Kura Oncology, Inc.
Biotechnology · Healthcare · United States
10.26
close · 2026-10-30
value
41
cheaper than peers41
quality
26
stronger fundamentals26
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | 14.7% | 100 |
| cash flow yield, latest year | -7.7% | 54 |
| price to sales | 12.74× | 47 |
| earnings yield, 2 years ago | -20.3% | 47 |
| earnings yield, 1 year ago | -19.7% | 45 |
| earnings yield, 3 years ago | -19.8% | 44 |
| cash flow yield, 2 years ago | -13.7% | 40 |
| cash flow yield, 3 years ago | -12.1% | 40 |
| earnings yield, latest year | -31.0% | 33 |
| price to book | 18.86× | 9 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 29.5% | 56 |
| debt to equity | 22.5% | 45 |
| operating margin | -431.5% | 35 |
| return on equity | -124.7% | 19 |
4 of 4 measures available
Facts
| market cap | $913M |
| free cash flow | -$129.8M |
| employees | 260 |
| first trade | 2015-09-16 |
| next earnings | 2026-08-12 |
| fundamentals updated | 2026-08-12 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.18 | -2.02 | -2.08 | -2.03 |
| free cash flow | -$70.7M | $133.8M | -$125.0M | -$110.7M |
| net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M |
| revenue | $67.5M | $53.9M | $0 | $0 |